Abstract
The interest on targeting adenosine A2A receptors in the realm of psychiatric diseases first arose based on their tight physical and functional interaction with dopamine D2 receptors. However, the role of central A2A receptors is now viewed as much broader than just controlling D2 receptor function. Thus, there is currently a major interest in the ability of A2A receptors to control synaptic plasticity at glutamatergic synapses. This is due to a combined ability of A2A receptors to facilitate the release of glutamate and the activation of NMDA receptors. Therefore, A2A receptors are now conceived as a normalizing device promoting adequate adaptive responses in neuronal circuits, a role similar to that fulfilled, in essence, by dopamine. This makes A2A receptors particularly attractive targets to manage psychiatric disorders since adenosine may act as go-between glutamate and dopamine, two of the key players in mood processing. Furthermore, A2A receptors also control glia function and brain metabolic adaptation, two other emerging mechanisms to understand abnormal processing of mood, and A2A receptors are important players in controlling the demise of neurodegeneration, considered an amplificatory loop in psychiatric disorders. Current data only provide an indirect confirmation of this putative role of A2A receptors, based on the effects of caffeine (an antagonist of both A1 and A2A receptors) in psychiatric disorders. However, the introduction of A2A receptors antagonists in clinics as anti-parkinsonian agents is hoped to bolster our knowledge on the role of A2A receptors in mood disorders in the near future.
Keywords: Adenosine, A2A receptor, caffeine, mood disorders, psychiatric diseases, anxiety, depression, schizophrenia, attention deficit hyperactivity disorder, ADHD
Current Pharmaceutical Design
Title: Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Volume: 14 Issue: 15
Author(s): Rodrigo A. Cunha, Sergi Ferre, Jean-Marie Vaugeois and Jiang-Fan Chen
Affiliation:
Keywords: Adenosine, A2A receptor, caffeine, mood disorders, psychiatric diseases, anxiety, depression, schizophrenia, attention deficit hyperactivity disorder, ADHD
Abstract: The interest on targeting adenosine A2A receptors in the realm of psychiatric diseases first arose based on their tight physical and functional interaction with dopamine D2 receptors. However, the role of central A2A receptors is now viewed as much broader than just controlling D2 receptor function. Thus, there is currently a major interest in the ability of A2A receptors to control synaptic plasticity at glutamatergic synapses. This is due to a combined ability of A2A receptors to facilitate the release of glutamate and the activation of NMDA receptors. Therefore, A2A receptors are now conceived as a normalizing device promoting adequate adaptive responses in neuronal circuits, a role similar to that fulfilled, in essence, by dopamine. This makes A2A receptors particularly attractive targets to manage psychiatric disorders since adenosine may act as go-between glutamate and dopamine, two of the key players in mood processing. Furthermore, A2A receptors also control glia function and brain metabolic adaptation, two other emerging mechanisms to understand abnormal processing of mood, and A2A receptors are important players in controlling the demise of neurodegeneration, considered an amplificatory loop in psychiatric disorders. Current data only provide an indirect confirmation of this putative role of A2A receptors, based on the effects of caffeine (an antagonist of both A1 and A2A receptors) in psychiatric disorders. However, the introduction of A2A receptors antagonists in clinics as anti-parkinsonian agents is hoped to bolster our knowledge on the role of A2A receptors in mood disorders in the near future.
Export Options
About this article
Cite this article as:
Cunha A. Rodrigo, Ferre Sergi, Vaugeois Jean-Marie and Chen Jiang-Fan, Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders, Current Pharmaceutical Design 2008; 14 (15) . https://dx.doi.org/10.2174/138161208784480090
DOI https://dx.doi.org/10.2174/138161208784480090 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets Urocortins: Putative Role in Cardiovascular Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19
Current Pharmaceutical Design NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Peculiarities of the Clinical Course of Oxidative Protein and Lipid Modification in Children with Acute Rheumatic Fever
Endocrine, Metabolic & Immune Disorders - Drug Targets PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Use of Dopaminergic Agents in the Treatment-Resistant Depression
Current Psychopharmacology High Throughput Screening and Structure-Activity Relationship Study of Potential α2A-Adrenoceptor Agonists by LANCETM cAMP Assay
Combinatorial Chemistry & High Throughput Screening The Medical Complications of Anorexia Nervosa and Their Treatments
Current Women`s Health Reviews The Oral and Intranasal Delivery of Propofol Using Chitosan Amphiphile Nanoparticles
Pharmaceutical Nanotechnology Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters Readjusting the Glucocorticoid Balance: An Opportunity for Modulators of 11β -Hydroxysteroid Dehydrogenase Type 1 Activity?
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Current Drug Therapy Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Therapy in Prion Diseases
Current Topics in Medicinal Chemistry